Modiodal (Modafinil)

Modafinil, the active ingredient in Modiodal, is a eugeroic presented as a tablet for oral use. It is prescribed to improve wakefulness in adults with narcolepsy, shift work sleep disorder, and, off‑label, in obstructive sleep apnea patients who experience residual daytime sleepiness.

GNH USA supplies Modiodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modiodal is a central nervous system stimulant used to address disorders of excessive daytime sleepiness.

- Narcolepsy: reduces daytime sleepiness and improves alertness. - Shift work sleep disorder: helps maintain wakefulness during scheduled work hours. - Obstructive sleep apnea (off‑label): may improve residual sleepiness in patients already receiving standard therapy.

Modiodal may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation. - Anxiety: feelings of nervousness or tension.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reactions requiring immediate medical attention. - Cardiovascular events: chest pain or arrhythmias in susceptible individuals. - Psychiatric disturbances: hallucinations or severe mood changes.

When prescribing Modiodal, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate history of hypertension or heart disease. - Psychiatric evaluation: screen for pre‑existing psychosis or severe anxiety. - Liver function: monitor in patients with hepatic impairment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Drug dependence: assess risk of misuse in patients with substance‑use history. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Modiodal can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase modafinil plasma levels. - CYP2C19 inhibitors (e.g., fluvoxamine): can raise exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: modafinil may reduce hormonal efficacy, requiring alternative contraception. - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Anticoagulants (warfarin): potential alteration of INR, requiring closer monitoring.